Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study

Subsai Kongsaengdao, Benchalak Maneeton, Narong Maneeton, Subsai Kongsaengdao, Benchalak Maneeton, Narong Maneeton

Abstract

Objective: This study aimed to identify possible improvements in disease-specific health-related quality of life (HRQoL) after multiple injections of botulinum toxin A over 24 weeks in Thai cervical dystonia (CD) patients.

Materials and methods: A 24-week prospective study comparing HRQoL of Thai CD patients before and after multiple injections of botulinum toxin A at 3-month intervals was performed. Disease-specific HRQoL was assessed by using the Cervical Dystonia Impact Profile-58 questionnaire (CDIP-58) and the Craniocervical Dystonia Questionnaire-24 (CDQ-24). General HRQoL was assessed by using the Medical Outcomes' 36-Item Short Form Health Survey (SF-36) and the EuroQoL 5-dimension questionnaire (EQ-5D). All the assessments were performed before and after the 24-week treatment period.

Results: A total of 20 CD patients were enrolled in this study from April to December 2011. CDIP-58 and CDQ-24 scores, which assess disease-specific HRQoL, showed a significant improvement after 24 weeks of treatment by botulinum toxin A (P<0.001). However, EQ-5D and SF-36 scores, which assess general HRQoL, showed no significant improvement after the treatment (P>0.05).

Conclusion: CD patients' disease-specific HRQoL improved after being treated with multiple botulinum toxin A injections. However, general HRQoL was not improved.

Keywords: 36-Item Short Form Health Survey; Cervical Dystonia Impact Profile-58 questionnaire; Craniocervical Dystonia Questionnaire-24; EuroQoL 5-dimension questionnaire; botulinum toxin A; cervical dystonia; the health-related quality of life.

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Lateral neck muscles.
Figure 2
Figure 2
Schematic diagram showing progression of 20 subjects from screening. Abbreviations: CDIP-58, Cervical Dystonia Impact Profile-58 questionnaire; CDQ-24, Craniocervical Dystonia Questionnaire-24; EQ-5D, EuroQoL 5-dimension questionnaire; SF-36, 36-Item Short Form Health Survey.

References

    1. Coelh M, Valadas AF, Mestre T, Ferreira JJ. Pain and quality of life in the treatment of cervical dystonia. Eur Neurol Rev. 2009;4(2):74–78.
    1. Geyer HL, Bressman SB. The diagnosis of dystonia. Lancet Neurol. 2006;5(9):780–790.
    1. Brashear A. The botulinum toxins in the treatment of cervical dystonia. Semin Neurol. 2001;21(1):85–90.
    1. Marras C, Van den Eeden SK, Fross RD, et al. Minimum incidence of primary cervical dystonia in a multiethnic health care population. Neurology. 2007;69(7):676–680.
    1. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Sampaio C. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database Syst Rev. 2005;1:CD004312.
    1. Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996;46(4):1066–1072.
    1. Walker FO. Botulinum toxin therapy for cervical dystonia. Phys Med Rehabil Clin N Am. 2003;14(4):749–766. vi.
    1. Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5(10):864–872.
    1. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699–1706.
    1. Ferreira JJ, Costa J, Coelho M, Sampaio C. The management of cervical dystonia. Expert Opin Pharmacother. 2007;8(2):129–140.
    1. Slawek J, Friedman A, Potulska A, et al. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol. 2007;22(2):95–100.
    1. Pekmezovic T, Svetel M, Ivanovic N, et al. Quality of life in patients with focal dystonia. Clin Neurol Neurosurg. 2009;111(2):161–164.
    1. Hakkinen A, Ylinen J, Rinta-Keturi M, Talvitie U, Kautiainen H, Rissanen A. Decreased neck muscle strength is highly associated with pain in cervical dystonia patients treated with botulinum toxin injections. Arch Phys Med Rehabil. 2004;85(10):1684–1688.
    1. Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry. 2001;71(2):193–199.
    1. Muller J, Wissel J, Kemmler G, et al. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry. 2004;75(5):749–753.
    1. Colosimo C, Pantano P, Calistri V, Totaro P, Fabbrini G, Berardelli A. Diffusion tensor imaging in primary cervical dystonia. J Neurol Neurosurg Psychiatry. 2005;76(11):1591–1593.
    1. Cano SJ, Warner TT, Linacre JM, et al. Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58) Neurology. 2004;63(9):1629–1633.
    1. Cano SJ, Hobart JC, Edwards M, et al. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology. 2006;67(12):2230–2232.
    1. van den Dool J, Tijssen MA, Koelman JH, Engelbert RH, Visser B. Determinants of disability in cervical dystonia. Parkinsonism Relat Disord. 2016 Aug 15; Epub.
    1. Leurmarnkul W. Properties testing of the retranslated SF-36 (Thai version) Thai J Pharm Sci. 2005;29(1–2):69–88.
    1. Ware JE., Jr SF-36 health survey update. Spine. 2000;25(24):3130–3139.
    1. Sakthong P, Kasemsup V. Health-related quality of life in Thai peritoneal dialysis patients. Asian Biomed. 2011;5(6):799–805.
    1. Herndon RM. Handbook of Neurologic Rating Scales. New York: Demos; 2006.
    1. Cohen-Gadol AA, Ahlskog JE, Matsumoto JY, Swenson MA, McClelland RL, Davis DH. Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic. J Neurosurg. 2003;98(6):1247–1254.
    1. Tongsiri S. The Thai Population-Based Preference Scores for EQ-5D Health States. London: London School of Hygiene and Tropical Medicine, University of London; 2009.
    1. Munchau A, Palmer JD, Dressler D, et al. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain. 2001;124(Pt 4):769–783.
    1. Kiss ZH, Doig-Beyaert K, Eliasziw M, et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain. 2007;130(Pt 11):2879–2886.
    1. Delnooz CC, Horstink MW, Tijssen MA, van de Warrenburg BP. Paramedical treatment in primary dystonia: a systematic review. Mov Disord. 2009;24(15):2187–2198.
    1. Tan NC, Chan LL, Tan EK. Hemifacial spasm and involuntary facial movements. QJM. 2002;95(8):493–500.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere